Dose escalation for metastatic spinal cord compression in patients with relatively radioresistant tumors.

  • Dirk Rades
  • Katja Freundt
  • Thekla Meyners
  • Amira Bajrovic
  • Hiba Basic
  • Johann H Karstens
  • Irenaeus A Adamietz
  • Ingeborg Wildfang
  • Volker Rudat
  • Steven E Schild
  • Juergen Dunst

Abstract

Radiotherapy alone is the most common treatment for metastatic spinal cord compression (MSCC) from relatively radioresistant tumors such as renal cell carcinoma, colorectal cancer, and malignant melanoma. However, the results of the "standard" regimen 30 Gy/10 fractions need to be improved with respect to functional outcome. This study investigated whether a dose escalation beyond 30 Gy can improve treatment outcomes.

Bibliographical data

Original languageEnglish
Article number5
ISSN0360-3016
Publication statusPublished - 2011
pubmed 20579816